Short answer
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) filed its Q1 2026 10-Q quarterly report on May 8, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $37M (up 0.1% year over year) with net income of −$8M.
Q1 2026 key financials · XBRL
- Revenue
- $37M
- +0.1% YoY
- Net income
- −$8M
- +98.1% YoY
- Operating margin
- -22.5%
- Gross margin
- 34.5%
- EPS (diluted)
- −$0.03
- +97.9% YoY
Source: XBRL data from the PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) Q1 2026 10-Q on SEC EDGAR. USD.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $37.2M, flat YoY; consumables $21.8M vs $20.1M, instruments $9.7M vs $11.0M
- Gross profit $12.8M vs gross loss $1.4M YoY
- Operating loss $8.4M vs $428.9M YoY
- Cash, equivalents and investments $276.0M vs $279.5M at December 31, 2025
- Headwinds: lower Vega sales and service revenue offset higher Revio sales and consumables growth
Risk Factors
- New tariff risk tied to U.S. government measures and trading-partner responses, including import and export restrictions
- Commercialization risk: Revio and Vega adoption may lag, causing obsolete inventory charges and losses on firm purchase commitments
- Funding risk: $200.0 million 2029 Notes and $441.0 million 2030 Notes outstanding amid negative operating cash flow
- Profitability risk: management does not expect profitability in 2026 despite expense-reduction initiatives
- Customer concentration risk: academic and government funding reductions could reduce sequencing demand
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other PACIFIC BIOSCIENCES OF CALIFORNIA, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.